background
manag
respiratori
viru
infect
prior
hematopoiet
cell
transplant
hct
difficult
examin
whether
respiratori
viru
detect
hct
influenc
requir
bronchoscopi
hospit
overal
surviv
follow
hct
method
prehct
weekli
posthct
nasal
wash
collect
day
patient
without
symptom
sampl
test
multiplex
polymeras
chain
reaction
respiratori
syncyti
viru
parainfluenza
virus
influenza
b
human
metapneumoviru
adenoviru
human
rhinovirus
coronavirus
bocaviru
result
patient
respiratori
virus
detect
prehct
overal
patient
virus
detect
prehct
fewer
day
aliv
hospit
lower
surviv
day
adjust
hazard
ratio
ahr
confid
interv
ci
p
patient
neg
sampl
risk
also
present
rhinoviru
alon
ahr
mortal
ci
p
differ
bronchoscopi
incid
seen
patient
without
respiratori
virus
ahr
ci
p
symptomat
patient
respiratori
virus
detect
increas
overal
mortal
compar
patient
without
virus
detect
unadjust
hr
ci
p
among
asymptomat
patient
detect
respiratori
virus
associ
increas
mortal
conclus
data
support
routin
test
respiratori
virus
among
symptomat
patient
hct
delay
transplant
viru
detect
feasibl
even
detect
rhinoviru
alon
studi
need
address
whether
asymptomat
patient
undergo
screen
respiratori
viru
detect
hct
decis
proceed
hematopoiet
cell
transplant
hct
patient
new
upper
respiratori
symptom
challeng
guidelin
cosponsor
nation
intern
societi
recommend
delay
hct
patient
pretranspl
upper
respiratori
tract
infect
urti
although
document
benefit
delay
limit
strength
evid
low
biii
potenti
disadvantag
delay
includ
progress
underli
diseas
logist
issu
regard
donor
patient
avail
benefit
delay
hct
may
depend
specif
virus
symptom
present
one
retrospect
analysi
pretranspl
urti
caus
respiratori
syncyti
viru
rsv
found
delay
hct
reduc
risk
pneumonia
transplant
anoth
studi
evalu
parainfluenza
viru
piv
infect
prehct
determin
complic
increas
hct
data
children
even
limit
mani
transplant
center
test
symptomat
patient
respiratori
virus
polymeras
chain
reaction
pcr
hct
delay
transplant
possibl
respiratori
symptom
present
respiratori
virus
includ
influenza
piv
rsv
human
metapneumoviru
hmpv
detect
preval
readili
detect
virus
includ
human
coronavirus
hcov
human
bocaviru
hbov
human
rhinovirus
hrv
uncertainti
exist
regard
proceed
hct
consequ
mild
urti
due
virus
unknown
center
collect
screen
pretranspl
nasal
specimen
decis
proceed
problemat
asymptomat
viral
shed
detect
evalu
clinic
outcom
associ
pretranspl
respiratori
virus
patient
follow
prospect
day
hct
multiplex
pcr
test
respiratori
virus
perform
nasal
wash
nw
lower
respiratori
tract
sampl
avail
determin
whether
detect
pretranspl
respiratori
viru
type
viru
accompani
symptom
influenc
patient
outcom
first
day
hct
primari
outcom
measur
includ
lower
respiratori
tract
diseas
requir
bronchoscopi
day
aliv
hospit
overal
mortal
prospect
studi
perform
allogen
hct
recipi
undergo
transplant
decemb
februari
fred
hutchinson
cancer
research
center
studi
part
surveil
studi
among
hct
recipi
follow
year
hct
follow
written
inform
consent
weekli
virolog
surveil
day
posttranspl
conduct
respiratori
sampl
studi
includ
collect
presenc
clinic
symptom
symptomat
surveil
surveil
nw
nasopharyng
swab
nw
preclud
clinic
oropharyng
swab
specimen
obtain
particip
least
weekli
hct
nw
collect
use
ml
salin
per
nostril
adult
mlnostril
children
combin
oropharyng
swab
test
research
specimen
gener
collect
within
day
schedul
hct
regardless
respiratori
symptom
studi
period
nw
routin
collect
respiratori
virus
patient
pretranspl
respiratori
symptom
therefor
clinic
sampl
may
collect
instead
research
sampl
research
sampl
collect
absenc
clinic
sampl
design
asymptomat
surveil
decemb
april
collect
pretranspl
screen
nw
institut
rsv
outbreak
collect
prehct
surveil
specimen
regardless
symptom
routin
children
age
year
novemb
collect
extend
includ
children
age
year
result
clinic
viral
test
symptomat
patient
patient
screen
rsv
outbreak
children
surveil
nw
known
order
provid
per
clinic
practic
pretranspl
sampl
collect
specif
research
test
result
report
real
time
respiratori
viru
detect
clinic
sampl
particularli
symptomat
patient
may
delay
hct
actual
transplant
may
occur
week
month
collect
initi
sampl
clinic
research
respiratori
sampl
collect
day
day
prehct
analyz
result
prehct
lower
respiratori
tract
sampl
also
includ
posthct
nw
specimen
collect
weekli
day
research
clinic
sampl
test
qualit
laboratorydevelop
pcr
assay
respiratori
virus
sampl
consid
posit
pcr
amplif
plot
cross
threshold
cycl
qualit
result
clinic
specimen
report
physician
clinic
sampl
test
convent
method
includ
viral
cultur
shell
vial
cultur
direct
fluoresc
antibodi
test
pcr
method
perform
accord
colleg
american
pathologist
standard
examin
primari
outcom
need
bronchoscopi
potenti
marker
underli
pneumonia
bronchoscopi
perform
routin
patient
suspect
lower
respiratori
tract
diseas
number
day
aliv
hospit
marker
resourc
util
overal
mortal
also
describ
whether
pretranspl
respiratori
virus
persist
caus
progress
diseas
follow
transplant
patient
characterist
compar
patient
without
prehct
respiratori
virus
via
test
categor
data
test
continu
data
cumul
incid
curv
use
estim
probabl
timetoev
outcom
incid
bronchoscopi
overal
mortal
first
day
death
first
day
treat
compet
risk
bronchoscopi
statist
signific
differ
event
rate
evalu
proport
hazard
regress
model
linear
regress
model
estim
differ
day
aliv
hospit
patient
group
factor
consid
potenti
confound
includ
model
differ
estim
coeffici
interest
seen
respiratori
virus
classifi
group
accord
likelihood
complic
base
literatur
group
includ
welldescrib
respiratori
viral
pathogen
rsv
hmpv
piv
influenza
b
adenoviru
group
includ
virus
potenti
less
like
caus
complic
includ
hrv
hcov
hbov
outcom
compar
patient
across
group
group
virus
group
virus
neg
simpl
adjust
model
also
examin
outcom
viral
infect
specif
antivir
therapi
avail
ie
influenza
rsv
well
patient
rhinoviru
unadjust
model
outcom
evalu
compar
patient
respiratori
viru
without
respiratori
virus
among
symptomat
asymptomat
patient
group
shown
figur
report
p
valu
base
wald
statist
adjust
made
multipl
comparison
respiratori
sampl
collect
patient
day
day
prior
allogen
hct
decemb
februari
figur
altogeth
patient
respiratori
sampl
test
pcr
convent
method
least
pretranspl
nw
collect
patient
patient
underw
bronchoscopi
without
upper
respiratori
specimen
collect
singl
pretranspl
sampl
collect
patient
sampl
sampl
surveil
sampl
collect
patient
symptomat
sampl
patient
one
respiratori
virus
detect
nw
patient
day
prehct
sampl
neg
patient
sampl
patient
characterist
within
group
defin
pretranspl
respiratori
virus
shown
tabl
patient
respiratori
virus
detect
averag
younger
p
abbrevi
cmv
cytomegaloviru
hct
hematopoiet
cell
transplant
pbsc
peripher
blood
stem
cell
standard
congenit
hematolog
disord
eg
sickl
cell
anemia
paroxysm
nocturn
hemaglobinuria
aplast
anemia
chronic
myeloid
leukemia
chronic
phase
myeloprolif
diseas
agnogen
myeloid
metaplasia
without
increas
blast
myelodysplast
syndrom
without
excess
blast
leukemia
lymphoma
remiss
high
congenit
immunodefici
diseas
hematolog
malign
like
highrisk
underli
diseas
p
neg
sampl
patient
respiratori
virus
detect
lower
baselin
lymphocyt
level
patient
neg
sampl
p
twentyfour
pediatr
patient
age
year
respiratori
virus
detect
compar
patient
age
year
p
tabl
fortyf
patient
group
virus
patient
group
virus
group
virus
rsv
piv
detect
asymptomat
surveil
compar
group
virus
p
tabl
among
patient
rsv
influenza
respect
receiv
treatment
andor
underw
delay
transplant
patient
rsv
treat
delay
patient
influenza
treat
delay
median
day
last
detect
hct
day
rsv
influenza
hrv
respect
bronchoscopi
perform
clinician
without
access
studi
result
although
clinic
test
result
known
differ
bronchoscopi
incid
within
day
posttranspl
seen
patient
without
respiratori
virus
adjust
hazard
ratio
ahr
confid
interv
ci
p
tabl
day
estim
time
first
bronchoscopi
confid
interv
ci
virusneg
group
ci
posit
group
figur
risk
requir
bronchoscopi
higher
although
significantli
patient
group
virus
without
pretranspl
viru
bronchoscopi
incid
differ
patient
group
virus
without
pretranspl
virus
tabl
day
probabl
estim
ci
group
ci
group
figur
patient
pretranspl
influenza
rsv
like
undergo
bronchoscopi
patient
without
pretranspl
virus
ahr
ci
p
patient
virus
higher
bronchoscopi
rate
respiratori
virusneg
patient
tabl
eighteen
patient
pretranspl
virus
lower
respiratori
tract
infect
lrti
virus
detect
bronchoalveolar
lavag
fluid
lung
biopsi
lrti
transplant
piv
hcov
adenoviru
hrv
influenza
hmpv
tabl
half
case
transplant
delay
respiratori
viru
detect
six
patient
lrti
transplant
die
day
death
relat
pretranspl
respiratori
virus
unrel
caus
tabl
four
patient
develop
lrti
posttranspl
hrv
pneumonia
surviv
brief
intens
care
unit
hospit
die
hrv
influenza
hmpv
tabl
day
aliv
hospit
first
day
posttranspl
use
measur
resourc
util
patient
pretranspl
respiratori
virus
spent
fewer
day
averag
aliv
hospit
without
respiratori
virus
detect
adjust
ci
day
p
tabl
figur
number
day
patient
aliv
hospit
similar
viru
group
figur
patient
either
group
significantli
fewer
day
without
pretranspl
respiratori
viru
tabl
patient
influenza
rsv
infect
differ
hospit
patient
hrv
respiratori
virus
significantli
fewer
averag
day
aliv
hospit
posttranspl
compar
patient
without
pretranspl
virus
tabl
patient
pretranspl
respiratori
virus
higher
overal
mortal
day
compar
patient
without
pretranspl
virus
ahr
ci
p
tabl
figur
show
overal
surviv
viral
statu
day
surviv
estim
ci
group
without
respiratori
virus
compar
ci
patient
respiratori
virus
detect
seven
death
occur
viru
group
death
group
tabl
overal
surviv
day
similar
group
significantli
lower
risk
surviv
compar
patient
without
pretranspl
respiratori
virus
figur
tabl
risk
death
differ
patient
influenza
rsv
without
pretranspl
virus
howev
pretranspl
rhinoviru
detect
significantli
associ
increas
risk
death
day
ahr
ci
p
tabl
five
death
day
group
death
patient
overal
directli
relat
pretranspl
respiratori
viru
infect
tabl
nineti
symptomat
patient
respiratori
virus
detect
prehct
compar
asymptomat
patient
asymptomat
patient
older
like
matchedrel
donor
receiv
peripher
blood
stem
cell
pbsc
lower
baselin
lymphocyt
level
symptomat
patient
supplementari
tabl
nine
asymptomat
patient
age
year
respiratori
virus
detect
compar
asymptomat
patient
year
old
incid
bronchoscopi
symptomat
patient
significantli
higher
among
respiratori
virus
without
unadjust
hr
ci
p
signific
differ
hospit
day
seen
unadjust
mean
differ
ci
p
symptomat
patient
respiratori
virus
detect
pretranspl
higher
overal
mortal
day
unadjust
hr
ci
p
compar
virusneg
patient
among
asymptomat
patient
pretranspl
surveil
sampl
signific
differ
unadjust
outcom
observ
patient
without
respiratori
virus
detect
risk
bronchoscopi
hr
ci
b
day
aliv
hospit
within
first
day
hct
pretranspl
respiratori
viral
statu
viru
group
group
includ
respiratori
syncyti
viru
human
metapneumoviru
parainfluenza
viru
influenza
b
adenoviru
p
group
includ
human
rhinoviru
human
coronaviru
human
bocaviru
p
box
repres
percentil
whisker
show
percentil
detect
pretranspl
evalu
patient
age
infect
patient
significantli
fewer
day
aliv
hospit
higher
overal
mortal
day
compar
uninfect
patient
mortal
appear
occur
mainli
symptomat
infect
patient
specif
pretranspl
viral
infect
analyz
pretranspl
influenza
rsv
confer
increas
risk
death
differ
outofhospit
day
although
prehct
detect
virus
associ
trend
toward
increas
incid
bronchoscopi
patient
pretranspl
virus
includ
hrv
significantli
fewer
day
aliv
hospit
patient
hrv
significantli
higher
day
mortal
uninfect
patient
one
possibl
reason
differ
patient
rsv
influenza
receiv
either
antivir
treatment
underw
delay
transplant
wherea
fewer
patient
hrv
transplant
delay
thu
remain
posit
condit
although
studi
indic
pretranspl
rhinoviru
infect
may
seriou
problem
hrv
report
caus
lower
respiratori
tract
diseas
outcom
similar
influenza
respiratori
virus
patient
studi
asymptomat
surveil
sampl
collect
unadjust
analysi
asymptomat
patient
surveil
sampl
found
increas
bronchoscopi
incid
overal
mortal
borderlin
signific
decreas
seen
day
outofhospit
patient
prehct
respiratori
viru
detect
suggest
asymptomat
patient
shed
respiratori
virus
hct
may
requir
care
util
resourc
hct
compar
shed
respiratori
virus
hct
patient
symptom
respiratori
viru
detect
signific
differ
bronchoscopi
incid
hospit
day
compar
uninfect
patient
although
trend
toward
lower
surviv
day
suggest
symptomat
patient
pretranspl
respiratori
viru
detect
higher
risk
advers
clinic
outcom
asymptomat
infect
patient
repres
largest
publish
studi
examin
outcom
patient
util
pretranspl
viral
surveil
molecular
diagnosi
analysi
individu
virus
remain
limit
small
number
patient
virusspecif
conclus
straightforward
similarli
analyz
pediatr
adult
patient
togeth
increas
power
analysi
make
difficult
draw
separ
conclus
adult
children
analysi
surveil
sampl
vs
symptomat
sampl
limit
small
number
event
preclud
multivari
analysi
result
respiratori
viru
test
known
symptomat
patient
manag
outcom
may
influenc
also
combin
data
sampl
collect
clinic
care
outbreak
investig
research
potenti
result
unforeseen
differ
group
although
abl
make
broad
conclus
outcom
patient
without
pretranspl
respiratori
viru
patient
without
symptom
predict
algorithm
everi
situat
possibl
respiratori
viru
test
closer
condit
onset
could
consid
particularli
patient
known
infect
tabl
addit
potenti
limit
molecular
test
detect
viral
rna
asymptomat
previous
treat
patient
may
repres
replic
viru
current
clinic
practic
guidelin
regard
time
transplant
respiratori
virus
present
larg
base
expert
opinion
studi
provid
evid
current
recommend
regard
delay
transplant
symptomat
respiratori
infect
justifi
virus
clinic
situat
risk
proceed
transplant
may
outweigh
risk
wait
viral
clearanc
thought
deliber
must
given
regard
underli
diseas
transplant
type
underli
immunosuppress
specif
virus
inform
may
also
assist
decis
regard
type
stem
cell
donat
pbsc
vs
bone
marrow
vs
cord
blood
condit
regimen
util
symptomat
viral
respiratori
diseas
diagnos
transplant
urgent
need
data
strengthen
current
clinic
practic
guidelin
advis
symptomat
patient
test
transplant
delay
feasibl
result
suggest
even
pretranspl
rhinoviru
infect
associ
poor
outcom
delay
transplant
possibl
milder
condit
regimen
consid
like
appli
patient
symptomat
rhinoviru
infect
research
assess
rhinoviru
associ
poor
outcom
need
data
suggest
surveil
asymptomat
patient
without
recent
histori
respiratori
diseas
prior
hct
may
necessari
howev
studi
specif
address
screen
asymptomat
patient
hct
warrant
applic
approach
children
remain
problemat
part
rel
children
studi
high
rate
pretranspl
virus
detect
posit
asymptomat
children
high
mortal
children
age
year
prehct
respiratori
virus
noteworthi
effect
treatment
unavail
mani
respiratori
virus
delay
hct
often
feasibl
data
emphas
need
intensifi
prevent
respiratori
viru
acquisit
transplant
improv
manag
strategi
includ
develop
new
antivir
agent
prophylact
strategi
supplementari
materi
avail
clinic
infecti
diseas
onlin
http
cidoxfordjournalsorg
supplementari
materi
consist
data
provid
author
publish
benefit
reader
post
materi
copyedit
content
supplementari
data
sole
respons
author
question
messag
regard
error
address
author
